CN114555090B - 墨蝶呤及其代谢物治疗辐射暴露的用途 - Google Patents

墨蝶呤及其代谢物治疗辐射暴露的用途 Download PDF

Info

Publication number
CN114555090B
CN114555090B CN202080069308.5A CN202080069308A CN114555090B CN 114555090 B CN114555090 B CN 114555090B CN 202080069308 A CN202080069308 A CN 202080069308A CN 114555090 B CN114555090 B CN 114555090B
Authority
CN
China
Prior art keywords
mir
subject
radiation
administration
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080069308.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114555090A (zh
Inventor
E·梅扎罗马
C·拉本德
R·米克尔森
V·亚科夫列夫
N·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ptc Medical Mp Co
Virginia Commonwealth University
Original Assignee
Ptc Medical Mp Co
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Medical Mp Co, Virginia Commonwealth University filed Critical Ptc Medical Mp Co
Priority to CN202411691224.1A priority Critical patent/CN119837879A/zh
Publication of CN114555090A publication Critical patent/CN114555090A/zh
Application granted granted Critical
Publication of CN114555090B publication Critical patent/CN114555090B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN202080069308.5A 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途 Active CN114555090B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411691224.1A CN119837879A (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
US62/882937 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411691224.1A Division CN119837879A (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途

Publications (2)

Publication Number Publication Date
CN114555090A CN114555090A (zh) 2022-05-27
CN114555090B true CN114555090B (zh) 2024-12-17

Family

ID=72148243

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080069308.5A Active CN114555090B (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途
CN202411691224.1A Pending CN119837879A (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411691224.1A Pending CN119837879A (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN114555090B (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
MX379061B (es) 2013-09-13 2025-03-04 Bioventures Llc Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
CN106794197A (zh) 2014-10-02 2017-05-31 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin";Maaike Berbée et al.;《Curr Drug Targets》;第11卷(第11期);第1366-1374页 *
"Tetrahydrobiopterin Protects against Radiation‑induced Growth Inhibition in H9c2 Cardiomyocytes";Zheng-Yi Zhang et al.;《Chin Med J》;第129卷(第22期);第2733-2740页 *
Maaike Berbée et al.."Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin".《Curr Drug Targets》.2010,第11卷(第11期),第1366-1374页. *

Also Published As

Publication number Publication date
CN114555090A (zh) 2022-05-27
US20220273661A1 (en) 2022-09-01
EP4454712A3 (en) 2025-01-01
FI4009978T3 (fi) 2024-11-01
JP2025098011A (ja) 2025-07-01
EP4009978A1 (en) 2022-06-15
HUE069012T2 (hu) 2025-02-28
EP4009978B1 (en) 2024-09-25
ES2994060T3 (en) 2025-01-16
CN119837879A (zh) 2025-04-18
SI4009978T1 (sl) 2025-03-31
BR112022002029A2 (pt) 2022-06-07
CA3146477A1 (en) 2021-02-11
RS66096B1 (sr) 2024-11-29
AU2020324435A1 (en) 2022-02-24
JP2022543655A (ja) 2022-10-13
IL290321B1 (en) 2026-04-01
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
PL4009978T3 (pl) 2025-02-24
PT4009978T (pt) 2024-11-05
WO2021026247A1 (en) 2021-02-11
IL290321A (en) 2022-04-01
JP7642611B2 (ja) 2025-03-10
MX2022001535A (es) 2022-03-04
AU2020324435B2 (en) 2026-03-19
DK4009978T3 (da) 2024-10-14
SMT202500089T1 (it) 2025-03-12
EP4454712A2 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
CN114555090B (zh) 墨蝶呤及其代谢物治疗辐射暴露的用途
EP3054952B1 (en) Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
WO2015023703A1 (en) Methods for the treatment of her2 amplified cancer
JP7854389B2 (ja) Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物
CN115605201A (zh) 血管紧张素ii 2型受体激动剂的新用途
KR20200103056A (ko) 고사이토카인혈증 및 중증 인플루엔자의 치료 또는 예방을 위한 방법 및 화합물
US8957107B2 (en) Method of treating scars and β-catenin-mediated disorders using Nefopam compounds
US20140037548A1 (en) Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
US20210187059A1 (en) Pharmaceutical combinations for treating cancer
JP2005512946A (ja) 選択的免疫調節法
HK40118407A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EA048135B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
EA052521B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
CN117379441A (zh) 华蟾素它灵在制备治疗肺纤维化的药物中的应用
HK40075560B (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
US20230330054A1 (en) Method for preventing or treating lung infection and lung inflammation
RU2831430C1 (ru) Соединения бензоксазинона в качестве двойных ингибиторов klk5/7
US20220273702A1 (en) Hydrogen sulfide and nitric oxide therapy for covid-19 infection
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
Liu et al. Mycophenolate mofetil inhibits ferroptosis by boosting autophagy to prevent pulmonary fibrosis
CN119745894A (zh) 一种通式化合物的用途
TW202310839A (zh) 用於預防或治療纖維化之醫藥組成物
JP2020132626A (ja) サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害
CN109939234A (zh) Foxp1基因及其抑制剂在制备抑制肺癌转移药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant